The therapeutic spectrum of infliximab and tumor necrosis factor immunomodulation in chronic inflammatory diseases.
This review summarizes the clinical results of Infliximab for the treatment of Crohn's disease, the limited data of its use in other digestive disorders and disorders related to the gastrointestinal tract. The etiology of these disorders remains enigmatic. As long as the precise etiology remains unknown, therapeutic options to treat these patients are predominantly symptomatic (i.e., immunosuppressive drugs or surgical intervention). To be able to develop more rational therapeutic regimens, it is pivotal to understand the immunopathological events that lead to, or are involved in, the pathogenesis of these diseases. Therefore, we also briefly summarize what at the present is known in this respect.
Ricart
Elena
E
Division of Gastrointestinal and Hepatological Diseases, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Bouma
Gerd
G
Peña
Amado Salvador
AS
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002446:Celiac Disease / Q000188:drug therapy* / Q000276:immunology; D002648:Child; D002908:Chronic Disease; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000276:immunology; D003424:Crohn Disease / Q000188:drug therapy / Q000191:economics / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000191:economics / Q000276:immunology; D000069285:Infliximab; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab